GLP-1 Series Week 6: Pancreatitis, Chronic Pancreatitis and Pancreatic Cancer What Does the Medical Research Actually Show?

GLP-1 medications have become one of the most talked-about treatments for diabetes and weight loss. With their growing use, questions about GLP-1 medications and pancreatitis have also become increasingly common.

Can GLP-1 medications cause pancreatitis?

Can acute pancreatitis become chronic?

Does chronic pancreatitis increase the risk of pancreatic cancer?

And most importantly, does taking a GLP-1 medication increase pancreatic cancer risk?

These questions sound like they should have simple yes-or-no answers.

They don’t.

This week we’re looking specifically at the pancreas and separating what medical research has established from what remains uncertain.

What Is the Pancreas?

The pancreas is an organ located behind the stomach that performs two extremely important jobs.

It produces digestive enzymes that help break down the food we eat, and it produces hormones involved in blood sugar regulation, including insulin and glucagon.

When the pancreas becomes inflamed, the condition is called pancreatitis.

There are two primary forms:

Acute pancreatitis develops suddenly.

Chronic pancreatitis involves persistent or recurrent inflammation that eventually causes permanent damage to pancreatic tissue.

Understanding the difference between the two is extremely important when discussing GLP-1 medications.

GLP-1 Medications and Acute Pancreatitis

Acute pancreatitis has been reported in people taking GLP-1 receptor agonists and appears in prescribing warnings for medications in this class.

Symptoms can include severe and persistent abdominal pain, sometimes radiating into the back, with or without nausea and vomiting.

But a warning doesn’t necessarily tell us how frequently an event occurs or prove that the medication caused every reported case.

That’s why randomized controlled trials are so important.

A 2025 systematic review and meta-analysis examined 62 randomized clinical trials involving 66,232 participants taking GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, exenatide and tirzepatide.

When researchers combined all of the studies, they found a modest statistical increase in pancreatitis, with a relative risk of 1.44.

However, when the studies were separated according to whether participants were taking other background medications, the increase was no longer statistically significant within those subgroups.

The researchers therefore concluded that there may be a small pancreatitis signal, but the relationship remains complicated and requires continued investigation. (PubMed)

Does This Mean GLP-1 Medications Cause Pancreatitis?

We need to be careful with that statement.

Pancreatitis has occurred in people taking these medications, and it is a recognized potential adverse event.

But pancreatitis has many other causes and risk factors, including gallstones, heavy alcohol use, very high triglycerides, certain medications and other medical conditions.

People with obesity and type 2 diabetes may already have some risk factors for pancreatic and gallbladder disease.

Therefore, the most scientifically accurate statement today is:

GLP-1 medications have been associated with acute pancreatitis and pancreatitis remains an important safety concern, but current evidence does not demonstrate that these medications commonly cause pancreatitis.

Can Acute Pancreatitis Become Chronic Pancreatitis?

Yes, in some circumstances.

But one episode of acute pancreatitis does not automatically mean someone will develop chronic pancreatitis.

Chronic pancreatitis generally results from ongoing or repeated pancreatic injury that eventually produces permanent structural changes and scarring.

That distinction matters because chronic pancreatitis carries consequences that extend well beyond an isolated episode of inflammation.

And one of those consequences is particularly important.

Chronic Pancreatitis and Pancreatic Cancer

Unlike the uncertain relationship between GLP-1 medications and pancreatic cancer, the association between chronic pancreatitis and pancreatic cancer is well established.

A systematic review and meta-analysis published in Clinical and Translational Gastroenterology examined 25 studies investigating pancreatitis and pancreatic ductal adenocarcinoma.

Researchers found a substantially elevated incidence of pancreatic cancer among people with chronic pancreatitis. They also found that the cumulative incidence increased with longer follow-up. (PubMed)

Another 2025 systematic review involving more than 432,000 people similarly found a significantly higher pancreatic cancer risk among people with a history of pancreatitis, with the association stronger for chronic than acute pancreatitis. (PubMed)

This doesn’t mean everyone with chronic pancreatitis develops pancreatic cancer.

They don’t.

It means chronic pancreatitis is an established risk factor for pancreatic cancer.

Why Can Chronic Inflammation Increase Cancer Risk?

Chronic inflammation means tissue is repeatedly being injured and repaired.

Over long periods of time, this environment can contribute to cellular and genetic changes associated with cancer development.

This relationship isn’t unique to the pancreas. Chronic inflammation in several organs has been associated with increased cancer risk.

But here’s where we need to be extremely careful not to make a scientific leap.

We cannot automatically conclude:

GLP-1 medication → acute pancreatitis → chronic pancreatitis → pancreatic cancer.

Medical research has not established that chain of events.

Each connection must be evaluated independently.

Do GLP-1 Medications Increase Pancreatic Cancer Risk?

At this point, randomized clinical trials have not demonstrated a significant overall increase in pancreatic cancer.

The same 2025 meta-analysis of 62 randomized trials found no statistically significant overall association between GLP-1 receptor agonist use and pancreatic cancer.

The reported relative risk was 1.30, but the confidence interval crossed 1.0, meaning the overall result wasn’t statistically significant. (PubMed)

One subgroup involving people taking background medications did show an association, while the subgroup without background medications did not.

That’s exactly the type of finding researchers continue to investigate.

But There Is an Important Limitation

Cancer can take many years to develop.

The average follow-up in that 2025 analysis was approximately 43.5 weeks, although individual studies ranged from one week to 198 weeks. (PubMed)

That is important context.

Randomized clinical trials are excellent for identifying many medication effects, but relatively rare cancers with long latency periods can require much longer follow-up and very large populations before researchers can confidently determine whether a small risk exists.

Therefore, saying:

“GLP-1 medications cause pancreatic cancer”

would not be supported by current evidence.

But saying:

“We have definitively proven there can never be a long-term pancreatic cancer risk”

would also go beyond what relatively short-duration studies can establish.

Long-term surveillance remains important.

The Difference Between Association and Causation

This is one of the most important lessons in this entire GLP-1 series.

If someone develops pancreatitis while taking a medication, that doesn’t automatically prove the medication caused the pancreatitis.

If someone develops pancreatic cancer after taking a GLP-1 medication, that doesn’t automatically prove the medication caused the cancer.

Researchers have to compare large groups of people, account for other risk factors and follow patients for sufficient periods of time.

That’s how medicine separates coincidence, association and causation.

What Symptoms Should Someone Know?

Anyone taking a GLP-1 medication should be aware of symptoms that could indicate pancreatitis.

These can include:

Severe or persistent upper abdominal pain

Pain that travels into the back

Nausea or vomiting

Significant abdominal tenderness

These symptoms shouldn’t simply be dismissed as the normal gastrointestinal effects of a GLP-1 medication.

Severe or persistent abdominal pain requires prompt medical evaluation.

What Does the Evidence Tell Us Today?

Here’s where the research currently stands:

Pancreatitis has been reported with GLP-1 receptor agonists.

A recent randomized-trial meta-analysis identified a modest overall pancreatitis signal, although that association wasn’t statistically significant after certain subgroup analyses. (PubMed)

Acute pancreatitis doesn’t automatically become chronic pancreatitis.

Repeated or persistent pancreatic injury can, however, contribute to chronic pancreatic disease.

Chronic pancreatitis is an established risk factor for pancreatic cancer. (PubMed)

Current randomized clinical trial evidence has not established that GLP-1 medications increase overall pancreatic cancer risk. (PubMed)

And because pancreatic cancer is relatively uncommon and may take years to develop, continued long-term research remains important.

The Bottom Line

When discussing GLP-1 medications, we shouldn’t exaggerate the risks.

But we shouldn’t dismiss legitimate questions either.

There is a difference between something being proven safe forever, something being proven dangerous, and something that medicine is still studying.

The pancreas deserves particular attention because pancreatitis is a recognized potential complication, while chronic pancreatitis itself is an established pancreatic cancer risk factor.

At this time, however, research has not demonstrated that GLP-1 medications cause chronic pancreatitis or pancreatic cancer.

That distinction matters.

Our goal throughout this series is not to promote GLP-1 medications.

It’s also not to make claims that the research cannot support.

Our goal is education.

Know what has been established.

Know what hasn’t.

Know what symptoms deserve attention.

And continue asking questions as longer-term research becomes available.

This article is for educational purposes only and isn’t intended to diagnose, treat or replace individualized medical advice. Anyone experiencing severe or persistent abdominal pain should seek prompt medical evaluation.

Sources

Research used for this article includes peer-reviewed systematic reviews and meta-analyses indexed by the U.S. National Library of Medicine’s PubMed database, including research published in Endocrinology, Diabetes & Metabolism, Clinical and Translational Gastroenterology, and Journal of Clinical Gastroenterology. (PubMed)